FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602405285> ?p ?o ?g. }

• W2602405285 abstract "15035 Background: Platinum and doxorubicin have different mechanisms of action, show no cross-resistance, and their toxicities do not overlap. Because pegylated liposomaI doxorubicin (Lipo-Dox was manufactured by TTY Biopharm Company Ltd. in Taiwan) appears to be a promising form of delivering doxorubicin with decrease of some of the most problematic toxicities, a combination with platinum should be assessed. Methods: An open-label, non-comparative, single center phase II clinical trial. Eligible patients must have histologically proven advance ovarian cancer with two-dimensioned measurable disease or evaluable disease (defined as CA-125 ≥ 40 U/ml), who have been treated with one or two previous platinum- and taxane-based regimen. All patients will hospitalize for 24 hours for treatment. The dose of platinum is fixed (cisplatin at 75 mg/m 2 or carboplatin at AUC=5) on D1 and the initial dose of pegylated liposomaI doxorubicin (Lipo-Dox) is 35 mg/m 2 on D2 at a 4-week interval. Results: Twenty patients were enrolled from July 2002 to January 2004 and follow up until June 2004. All eligible patients are assessable for response and toxicity. The overall response rate was 80%. Of the 20 patients eligible for response evaluation, 10 (50%) patients had a complete response, 6 (30%) had partial response, 3 (15%) were with stable disease, and 1 (5%) showed progressive disease. An overall response (OR) was achieved in 80% of patients. In patients achieving an OR based on WHO criteria, median CA125 levels declined from 142 U/ml (range, 13–3670 U/ml) during the baseline to 26.5 U/ml (range, 5–375 U/ml) during the last cycle. Median time to response was 65 days (range, 12–188 days). Median duration of response was 471 days (range 146–1085 days). Furthermore, the median time to progression was 481 days (range, 138–1136 days). The main toxicity was myelosuppression, with grade 3 and 4 neutropenia in 3 patients, anemia in 4 patients, and leukopenia in 2 patients. Conclusions: Based on effectiveness and toxicity advantages, the combination of pegylated liposomaI doxorubicin (Lipo-Dox) and platinum should be considered in patients with advanced ovarian cancer in late relapse. No significant financial relationships to disclose." @default.
• W2602405285 created "2017-04-07" @default.
• W2602405285 creator A5009707114 @default.
• W2602405285 creator A5018933956 @default.
• W2602405285 creator A5032340945 @default.
• W2602405285 creator A5037320559 @default.
• W2602405285 creator A5065642478 @default.
• W2602405285 creator A5068860536 @default.
• W2602405285 creator A5086212262 @default.
• W2602405285 date "2006-06-20" @default.
• W2602405285 modified "2023-09-23" @default.
• W2602405285 title "Pegylated liposomal doxorubicin and platinum in patients with advanced ovarian cancer in late relapse (>6 months)" @default.
• W2602405285 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.15035" @default.
• W2602405285 hasPublicationYear "2006" @default.
• W2602405285 type Work @default.
• W2602405285 sameAs 2602405285 @default.
• W2602405285 citedByCount "0" @default.
• W2602405285 crossrefType "journal-article" @default.
• W2602405285 hasAuthorship W2602405285A5009707114 @default.
• W2602405285 hasAuthorship W2602405285A5018933956 @default.
• W2602405285 hasAuthorship W2602405285A5032340945 @default.
• W2602405285 hasAuthorship W2602405285A5037320559 @default.
• W2602405285 hasAuthorship W2602405285A5065642478 @default.
• W2602405285 hasAuthorship W2602405285A5068860536 @default.
• W2602405285 hasAuthorship W2602405285A5086212262 @default.
• W2602405285 hasConcept C121608353 @default.
• W2602405285 hasConcept C126322002 @default.
• W2602405285 hasConcept C143998085 @default.
• W2602405285 hasConcept C2776694085 @default.
• W2602405285 hasConcept C2780427987 @default.
• W2602405285 hasConcept C2781303535 @default.
• W2602405285 hasConcept C29456083 @default.
• W2602405285 hasConcept C71924100 @default.
• W2602405285 hasConceptScore W2602405285C121608353 @default.
• W2602405285 hasConceptScore W2602405285C126322002 @default.
• W2602405285 hasConceptScore W2602405285C143998085 @default.
• W2602405285 hasConceptScore W2602405285C2776694085 @default.
• W2602405285 hasConceptScore W2602405285C2780427987 @default.
• W2602405285 hasConceptScore W2602405285C2781303535 @default.
• W2602405285 hasConceptScore W2602405285C29456083 @default.
• W2602405285 hasConceptScore W2602405285C71924100 @default.
• W2602405285 hasLocation W26024052851 @default.
• W2602405285 hasOpenAccess W2602405285 @default.
• W2602405285 hasPrimaryLocation W26024052851 @default.
• W2602405285 hasRelatedWork W1224191223 @default.
• W2602405285 hasRelatedWork W1982849070 @default.
• W2602405285 hasRelatedWork W1993880164 @default.
• W2602405285 hasRelatedWork W1995993811 @default.
• W2602405285 hasRelatedWork W2010230997 @default.
• W2602405285 hasRelatedWork W2170498496 @default.
• W2602405285 hasRelatedWork W2320097775 @default.
• W2602405285 hasRelatedWork W2362217537 @default.
• W2602405285 hasRelatedWork W2363732038 @default.
• W2602405285 hasRelatedWork W2407788778 @default.
• W2602405285 isParatext "false" @default.
• W2602405285 isRetracted "false" @default.
• W2602405285 magId "2602405285" @default.
• W2602405285 workType "article" @default.